Journal of Inflammatory Bowel Diseases & Disorders

ISSN: 2476-1958

Open Access

Current Issue

Volume 5, Issue 2 (2020)

    Editorial Note Pages: 1 - 2

    Novel Discoveries in Inflammatory Bowel Disease

    Hakan Alagozlu*

    Share this article
    Case Report Pages: 1 - 5

    Sustained Histologic Remission (Complete Mucosal Healing) 12 Years after One-Time Treatment of Refractory Ulcerative Colitis with Novel Combination Therapy: A Case Report

    Jay Pravda*, Richard Gordon and Pamela B. Sylvestre

    Ulcerative colitis is a major form of chronic inflammatory bowel disease affecting millions of individuals worldwide. It most often strikes in the prime of life, during late adolescence and early adulthood. Individuals with ulcerative colitis experience life-long reoccurring and unpredictable episodes of abdominal pain and bloody diarrhea lasting from weeks to months. This results in significant emotional and psychological burdens leading to life-long disruption of daily activities and quality of life. Environmental factors acting in concert with genetic, epigenetic, and microbiome influences are thought to trigger an immune abnormality leading to the chronic colonic inflammation observed in this condition. However, despite extensive research, a primary antecedent immune vulnerability has not been demonstrated in patients or healthy family members. Current therapy is primarily focused on suppressing or modulating the immune response, which is not curative. Other therapeutic modalities such as fecal microbiota transplantation and probiotics are not recommended as viable therapy options. Recent experimental data suggest a build-up of hydrogen peroxide in colonic epithelial cells as a causal factor in the development of this disease. Herein we describe a patient with a 39-year history of ulcerative colitis refractory to standard medical therapy including oral and rectal 5-aminosalicylic acid, oral and rectal steroids in addition to immunosuppressive agents such as 6-mercaptopurine. The patient received the recommended doses of these medications for months at a time in varied combinations without significant improvement. He subsequently received a novel combination therapy aimed at reducing colonic hydrogen peroxide. Histologic remission was achieved 6 weeks after this initial therapy. Colonoscopic evaluation 12-years after initial therapy revealed complete and sustained mucosal healing with histologic restitution to normal colonic mucosa. The patient reports having normal bowel movements during this 12-year period.
    Research Article Pages: 1 - 5

    Use of Narrow Band Imaging Colonoscopy in Diagnosis of Ulcerative Colitis Patients

    Khaled A. Aaty, Ayman Shamseya, Ezzat Aly, Moamen A. Fawzy* and Reem Ezzat

    Ulcerative colitis is a disease of increasing incidence and may progress to colonic cancer. Early detection of dysplastic changes is required. NBI is an added imaging procedure that is supposed to increase the yielding of diagnosis of ulcerative colitis.

    Aim of the study: Validate the relation between histological pattern and NBI findings in diagnosing ulcerative colitis.

    Patients and methods: 50 patients with diagnosed ulcerative colitis in Alexandria University Hospital were examined by colonoscopy and NBI then biopsies were taken from areas with detected lesions and histopathological examination was done.

    Results: Patients were divided into active (27) and inactive (23) according to the clinical performance. From the 23 patients that were supposed to be inactive, 14 showed honeycomb appearance and 7 showed irregular vascular mucosal patterns by NBI examination. Histopathological examination revealed metaplasia in 55% of the patients that were under the category of inactive patients. There was a significant correlation between histological examination and NBI findings. NBI showed sensitivity of 58.3%, specificity of 100%, PPV of 100%, NPV of 23% and accuracy of 62.9% in active patients.

    Conclusion: NBI is a valuable tool that can add value to colonoscopic examination in patients with ulcerative colitis.

    Perspective Pages: 1 - 2

    Clinical and Socio-Demographic Characteristics of Inflammatory Bowel Disease Patients in Gaza: A Cross-Sectional Descriptive Study

    Khamis Alessi, Hamza Yazji, Fekri Hamad, Saed Ouda*, Mohammed Alkhatib and Qusay Abdoh

    Background:The global incidence of Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC) and Crohn's Disease (CD), is in the rise. Despite the presence of some international studies that described the different patterns and characteristics if IBD, still however, we don't have a national epidemiological or descriptive data especially in Gaza Strip. The aim of this study is to identify socio-demographic and clinical characteristics of IBD among patients with IBD in Gaza.

    Short Communication Pages: 1 - 3

    Role/Risks of Proton Pump Inhibitors and Infliximab in IBD Patients

    Lim Vuanghao*

    Proton Pump Inhibitors (PPIs) are the most generally endorsed class of medicine for the treatment of indigestion and corrosive related issues. They work by obstructing the site of corrosive creation in the parietal cell of the stomach. Infliximab, a chimeric monoclonal antibody, is a medication used to treat a number of autoimmune diseases mainly Ulcerative Colitis (UC) and Crohn's Disease (CD). Infliximab targets TNF, thought to be more related to Th1 cytokines.

Relevant Topics


tempobet giriş

tempobet giriş


tipobet yeni giriş adresi tipobet e yeni giriş tipobet güncel giriş adresi imajbet giriş adresi

mobilbahis giriş

arrow_upward arrow_upward